- TRADE NAME: Alimta (Lilly)
- INDICATIONS: Non-squamous non-small cell lung cancer, mesothelioma (in combination with cisplatin)
- CLASS: Antimetabolite, Folic acid antagonist
- HALF-LIFE: 3.5 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Clozapine, Digoxin, Leflunomide, Meloxicam, Natalizumab, Nephrotoxic drugs, NSAIDs, Phenytoin, Pimecrolimus, Probenecid, Pyrimethamine, Sipuleucel-T, Tacrolimus, Trastuzumab, Vaccines
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of pemetrexed in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/24/2024
